Skip to content
lifestyle.clientim.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
SpyGlass Pharma, Inc.
SpyGlass Pharma to Participate in Upcoming Investor Conferences
May 21, 2026
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
May 18, 2026
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 14, 2026
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
March 9, 2026
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
March 4, 2026
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
February 20, 2026
SpyGlass Pharma Announces Pricing of Initial Public Offering
February 19, 2026
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System
January 20, 2026